Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer
NCT ID: NCT02921646
Last Updated: 2020-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
8 participants
INTERVENTIONAL
2017-07-10
2019-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer
NCT02342847
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
NCT00767273
Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
NCT00112697
A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer
NCT03902600
Patient Reported Outcomes Registry in Patient With Cancer Cachexia
NCT02983500
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
energetic expenditure measure
To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
Measure of resting energetic expenditure
measure of resting energetic expenditure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measure of resting energetic expenditure
measure of resting energetic expenditure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient older than 18 years
* Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel.
* At least one measurable target lesion
* Patient signed consent for Energie-Pancreas study participation
Exclusion Criteria
* Major general status alteration ( Performance status = 3 or 4 at inclusion)
* Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (\< 1 month), ongoing Healing, hyperthyroidism.
* Smoker
* Patient deprived of his liberty, under guardianship, curator.
* Pregnant patient or breastfeeding
* Claustrophobic patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Center Eugene Marquis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julien Edeline, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Eugène Marquis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Eugène Marquis
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-4-32-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.